1. Home
  2. CGON vs OPRA Comparison

CGON vs OPRA Comparison

Compare CGON & OPRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • OPRA
  • Stock Information
  • Founded
  • CGON 2010
  • OPRA 1996
  • Country
  • CGON United States
  • OPRA Norway
  • Employees
  • CGON N/A
  • OPRA N/A
  • Industry
  • CGON
  • OPRA Computer Software: Prepackaged Software
  • Sector
  • CGON
  • OPRA Technology
  • Exchange
  • CGON NYSE
  • OPRA Nasdaq
  • Market Cap
  • CGON 1.3B
  • OPRA 1.3B
  • IPO Year
  • CGON 2024
  • OPRA 2018
  • Fundamental
  • Price
  • CGON $23.74
  • OPRA $16.98
  • Analyst Decision
  • CGON Strong Buy
  • OPRA Strong Buy
  • Analyst Count
  • CGON 11
  • OPRA 5
  • Target Price
  • CGON $62.90
  • OPRA $24.90
  • AVG Volume (30 Days)
  • CGON 2.0M
  • OPRA 578.6K
  • Earning Date
  • CGON 05-20-2025
  • OPRA 04-28-2025
  • Dividend Yield
  • CGON N/A
  • OPRA 4.66%
  • EPS Growth
  • CGON N/A
  • OPRA N/A
  • EPS
  • CGON N/A
  • OPRA 0.93
  • Revenue
  • CGON $1,139,000.00
  • OPRA $521,494,000.00
  • Revenue This Year
  • CGON N/A
  • OPRA $20.00
  • Revenue Next Year
  • CGON $16,237.24
  • OPRA $15.66
  • P/E Ratio
  • CGON N/A
  • OPRA $18.46
  • Revenue Growth
  • CGON 461.08
  • OPRA 26.68
  • 52 Week Low
  • CGON $14.80
  • OPRA $10.11
  • 52 Week High
  • CGON $40.47
  • OPRA $22.50
  • Technical
  • Relative Strength Index (RSI)
  • CGON 49.91
  • OPRA 56.07
  • Support Level
  • CGON $21.00
  • OPRA $17.01
  • Resistance Level
  • CGON $30.23
  • OPRA $17.62
  • Average True Range (ATR)
  • CGON 2.33
  • OPRA 0.63
  • MACD
  • CGON 0.06
  • OPRA 0.23
  • Stochastic Oscillator
  • CGON 30.94
  • OPRA 81.89

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About OPRA Opera Limited

Opera Ltd is a world-wide internet brand with a large, engaged, and growing base. It offers users products and services that include a variety of PC and mobile browsers, Opera Gaming portals and development tools, Opera News content recommendation products, and a number of e-commerce products and services. Its browser's features include tabbed browsing, data savings, PC/mobile sync, and numerous features focused on privacy and security, including ad blocking and a built-in VPN. Its browser products include Opera Mini, Opera Browser for Android and iOS, Opera for Computers, Opera GX and Opera GX Mobile, separate browsers tailored for gamers. Geographically, the company generates maximum revenue from the United States, followed by Singapore, Nigeria, Russia, and other locations.

Share on Social Networks: